The Irish setter puppies are known for their striking deep red coat and energetic nature, making them delightful pets for those able to meet their active lifestyle needs. However, like many breeds, they are susceptible to certain hereditary conditions, one of the most serious being globoid cell leukodystrophy, also known as Krabbe disease.
Originally bred as gun dogs registered in the UK Kennel Club's gundog group, Irish setters are now more commonly cherished as family companions. Their high energy and love of outdoor activity require substantial exercise, while their beautiful coats demand regular grooming to maintain shine and minimise shedding indoors.
This breed generally enjoys a relatively long lifespan of 10-15 years, but unfortunately, some dogs may be affected by inherited diseases such as globoid cell leukodystrophy (GLD). GLD is a rare, fatal neurological disorder caused by a deficiency of the lysosomal enzyme galactocerebrosidase (GALC). This enzyme deficiency results in the build-up of toxic substances like psychosine that damage the protective myelin sheath of nerve cells, leading to progressive nervous system decline.
GLD, or Krabbe disease, typically appears during early puppyhood—between one to three months of age. Affected dogs initially seem healthy but soon develop symptoms including muscle weakness, tremors, uncoordinated movements (ataxia), behavioural changes, seizures, loss of motor control, and even blindness or deafness. These neurological signs worsen progressively, usually resulting in death or humane euthanasia within the first year because the condition has no cure.
Globoid cell leukodystrophy is inherited in Irish setters via an autosomal recessive pattern. This means a puppy must inherit two copies of the defective GALC gene mutation—one from each parent—to develop the disease. Carriers have one defective gene but do not show symptoms themselves. Knowing the genetic status of prospective parent dogs allows breeders to make informed mating choices to prevent producing affected puppies.
Because globoid cell leukodystrophy is fatal and untreatable, prevention through careful breeding is essential. DNA testing for the GALC mutation is widely available in the UK and is a critical tool for breeders committed to maintaining the health and wellbeing of Irish setters. By testing breeding stock, carriers and affected dogs can be identified, and breeding plans adjusted accordingly to avoid mating carriers to carriers or affected dogs.
Testing process: A simple DNA sample is collected by a vet—usually via cheek swab or blood sample—and sent to an accredited laboratory. Results typically come back in a few weeks, informing breeders of a dog’s genetic status as clear, carrier, or affected.
Reputable Irish setter breeders routinely test for globoid cell leukodystrophy as part of their health screening protocols. Responsible breeders will never knowingly breed two carriers or affected dogs together, aiming instead to pair carriers only with clear dogs to gradually eliminate the defective gene from the population while preserving genetic diversity.
Early genetic awareness combined with veterinary guidance supports the gradual reduction of globoid cell leukodystrophy in the breed without compromising the wider gene pool or the breed's desired characteristics.
If you own an Irish setter or are considering adding one to your family, it is wise to ask your breeder or shelter about any DNA health testing performed, including screening for globoid cell leukodystrophy. If you already have a dog and are planning to breed, consult your vet about testing to understand your dog’s status and how it may affect breeding choices.
Being informed helps protect the breed’s future and ensures your companion’s health and comfort.
For more information or to find reputable breeders who test for this condition, always consult veterinary specialists and recognised breeder clubs associated with Irish setters.